drugset
drugset / Trial / NCT05536323

Bolus Versus Continuous Remimazolam for Anesthetic Induction

NCT05536323 ↗

Unknown 62 enrolled Kangbuk Samsung Hospital
RandomizedParallel-groupTriple-blindOther

Summary

Remimazolam is a newly introduced intravenous anesthetic, with rapid onset and offset. Although it is known to cause less hemodynamic instability, the incidence hypotension is the one of the most frequent adverse events with its use. For anesthetic induction, remimazolam can be used either as bolus dose or as continuous infusion. This study is aimed to investigate the incidence of hypotension after anesthetic induction with bolus (0.14-0.33 mg/kg) or continuous (12 mg/kg/hr) remimazolam administration.

Timeline

Start
2023-07-01
Primary completion
2023-11-01
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Remimazolam Small molecule 0.14 mg/kg Intravenous
Subject Remimazolam Small molecule 0.19 mg/kg Intravenous
Subject Remimazolam Small molecule 0.25 mg/kg Intravenous
Subject Remimazolam Small molecule 0.33 mg/kg Intravenous
Subject Remimazolam Small molecule 12 mg/kg Intravenous

Indications

No indication recorded.